SIRT6 and celiac disease: In addition, IMU-856, a small molecule SIRT6 regulator, was shown to be safe and well tolerated in a clinical trial in celiac disease patients, supporting once-daily dosing, and to improve relevant pharmacodynamic parameters during gluten exposure, suggesting that SIRT6 may be a potential therapeutic target (Daveson et al., 2025).